Inhalation Anesthesia Market Report 2026

The inhalation anesthesia market size has grown strongly in recent years. It will grow from $1.64 billion in 2025 to $1.78 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising surgical procedures, increasing hospital investments, technological advancements in anesthesia equipment, growing awareness of patient safety, expanding healthcare infrastructure.

The inhalation anesthesia market size is expected to see strong growth in the next few years. It will grow to $2.51 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to adoption of AI-assisted anesthesia, demand for sustainable anesthetic agents, integration of IoT in operating rooms, growth in outpatient surgeries, development of smart anesthesia delivery systems. Major trends in the forecast period include enhanced patient safety protocols, advanced anesthesia delivery systems, minimally invasive surgery support, real-time anesthesia monitoring, environmentally friendly anesthetic agents.

The growing geriatric population is expected to drive the expansion of the inhalation anesthesia market during the forecast period. An increasing number of older adults is contributing to higher demand for inhalation anesthesia, as this population is more susceptible to degenerative diseases and chronic conditions, which in turn leads to a greater number of surgical procedures and therapeutic interventions. Additionally, the rising elderly population, which is more prone to conditions such as cardiovascular, neurological, respiratory, and degenerative disorders, is further supporting market growth. Administering anesthesia through the intravenous route is often challenging in geriatric patients due to fragile or damaged blood vessels and issues related to patient compliance. For example, in July 2024, the UK Parliament’s House of Commons Library, a UK-based government body, reported that in 2022 there were 12.7 million people aged 65 years or older in the UK. This figure is projected to increase to 22.1 million by 2072, representing 27% of the total population. Consequently, the expanding geriatric population is anticipated to increase demand for inhalation anesthesia over the forecast period.

The increasing prevalence of chronic diseases is expected to drive the growth of the inhalation anesthesia market in the coming years. Chronic diseases are long-term health conditions that persist for extended periods, typically lasting three months or longer. Inhalation anesthesia plays a vital role in healthcare, as it is essential for maintaining patient comfort and safety during surgical procedures that are often required for the diagnosis, treatment, or management of many chronic conditions. For example, in September 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that approximately 41 million deaths worldwide - representing 74% of all global deaths - are attributed annually to non-communicable or chronic diseases. These included 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2 million deaths from diabetes. As a result, the growing burden of chronic diseases is expected to fuel the expansion of the inhalation anesthesia market.

In November 2024, Sedana Medical AB, a Sweden-based supplier of inhaled sedation and inhalation anesthesia products, acquired Innovatif Cekal Sdn Bhd for USD 3.6 million (34 million SEK). Through this acquisition, Sedana Medical seeks to strengthen its supply chain control, reduce manufacturing costs, and secure long-term production capacity for its inhalation anesthesia devices by internalizing the manufacturing of the Sedaconda ACD and its associated accessories. Innovatif Cekal Sdn Bhd is a Malaysia-based company that provides device components and contract manufacturing services for the Sedaconda ACD, a critical device used to deliver volatile inhalation anesthetics to mechanically ventilated patients.

Major companies operating in the inhalation anesthesia market are AbbVie Inc., Baxter International Inc., Sandoz AG, Piramal Enterprises Limited, Fresenius SE & Co KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co Ltd, Lunan Pharmaceutical Group Co Ltd, Troikaa Pharmaceuticals Ltd, Dechra Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Maruishi Pharmaceutical Co Ltd, Nikko Chemicals (Japan), GlaxoSmithKline PLC, Boehringer Ingelheim International GmbH, Halocarbon Products Corporation, Abbott Laboratories, Baxter Healthcare (distinct manufacturing division) , Fresenius Kabi AG, Sedana Medical AB.

North America was the largest region in the inhalation anesthesia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalation anesthesia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalation anesthesia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the inhalation anesthesia market by increasing the cost of importing anesthetic gases, precision delivery equipment, and monitoring devices. Hospitals and ambulatory surgical centers in regions such as Asia-Pacific and Europe face higher procurement costs, particularly for imported Sevoflurane and Desflurane. While some domestic manufacturers benefit from reduced foreign competition, overall supply chain delays have led to cost optimization strategies and increased investment in local production and innovation of efficient anesthesia solutions.

The inhalation anesthesia market research report is one of a series of new reports that provides inhalation anesthesia market statistics, including inhalation anesthesia industry global market size, regional shares, competitors with a inhalation anesthesia market share, detailed inhalation anesthesia market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation anesthesia industry. This inhalation anesthesia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inhalation anesthesia refers to medications administered in operating rooms to induce and maintain general anesthesia. Along with other therapeutic effects, these agents cause varying levels of sedation, ranging from mild drowsiness to deep unconsciousness, including full general anesthesia. Inhalation anesthesia is commonly used for both the induction and maintenance of general anesthesia during surgical procedures.

The main products in the inhalation anesthesia market include sevoflurane, desflurane, isoflurane, and nitrous oxide. Isoflurane is an inhaled general anesthetic used to initiate and sustain general anesthesia. It works by relaxing muscles and decreasing pain sensitivity through alterations in tissue excitability. The applications of inhalation anesthesia include induction and maintenance of anesthesia, and the primary end users are hospitals and ambulatory surgical centers.

The inhalation anesthesia market consists of sales of nitrous oxide, halothane, isoflurane, desflurane, and sevoflurane. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.